Compare National Energy Services Reunited Corp Ordinary Shares (NESR) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Energy Services Reunited Corp Ordinary Shares vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? National Energy Services Reunited Corp Ordinary Shares trades at $19.71 (market cap $2.12B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $19.48 (market cap $60.06B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 28.3× National Energy Services Reunited Corp Ordinary Shares's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while National Energy Services Reunited Corp Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold National Energy Services Reunited Corp Ordinary Shares for 0 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 6 Days on average.
| NESR | TAK | |
|---|---|---|
Market Cap | $2.12B | $60.06B |
Volume | 3,257,316 | 2,925,042 |
Sector | Energy | Health |
52-Week High | $36.31 | $19.05 |
52-Week Low | $10.41 | $13.23 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.24B | $87.89B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NESR trades at $21.03, up 0.62% today, with neutral technical signals and strong fundamental momentum. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations by 25%. Revenue growth remains robust, driven by Middle East operations including the Jafurah gas field expansion. Analyst sentiment is overwhelmingly positive with 83% buy ratings and a consensus price target of $41.80, representing nearly 100% upside potential.
The outlook remains favorable with projected revenue growth to $1.6B in 2026 and net profit doubling to $93M. Key risks include execution pressure from premium valuation and regional geopolitical uncertainties. The recent lithium extraction deal with Saudi Aramco provides additional growth optionality, though capital demands remain elevated. Current levels offer attractive entry for growth-oriented investors despite technical neutrality.
TAK trades at $18.52, down 0.86% on the day. The stock shows mixed signals with a bullish technical outlook from moving averages but neutral oscillators. Recent financials reveal a net income margin of -3.54% for 2026, though revenue remains stable near $4.6 trillion. Positive developments include the launch of ORZEYFUL for narcolepsy and FDA priority review for zasocitinib, highlighting a robust pipeline. Cash flow improved to $209.8 billion in 2026 from a negative position in 2025.
Outlook: TAK's strong analyst support (83% buy ratings) and promising drug pipeline offer growth potential, but profitability concerns and high P/E of 51.56 pose risks. Investors should weigh pipeline successes against current negative margins and elevated valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Energy Services Reunited Corp Ordinary Shares
National Energy Services Reunited Corp (NESR) is a Houston-based oilfield services company that provides drilling, evaluation, and production services, including hydraulic fracturing, cementing, coiled tubing, and directional drilling, to oil and gas operators. It focuses primarily on markets across the Middle East, North Africa, and Asia Pacific.
Read more on NESR →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
